TY  - JOUR
AU  - Manso, Luis
AU  - Hernando, Cristina
AU  - Galán, María
AU  - Oliveira, Mafalda
AU  - Cabrera, Miguel A
AU  - Bratos, Raquel
AU  - Rodríguez, César A
AU  - Ruiz-Borrego, Manuel
AU  - Blanch, Salvador
AU  - Llombart-Cussac, Antonio
AU  - Delgado-Mingorance, Juan I
AU  - Álvarez-Busto, Iñaki
AU  - Gallegos, Isabel
AU  - González-Cortijo, Lucía
AU  - Morales, Serafín
AU  - Aguirre, Elena
AU  - Hernando, Blanca A
AU  - Ballesteros, Ana
AU  - Alés-Martínez, José E
AU  - Reboredo, Cristina
AU  - Oltra, Amparo
AU  - González-Cao, María
AU  - Santisteban, Marta
AU  - Malón, Diego
AU  - Echeverría, Isabel
AU  - García-Garre, Elisa
AU  - Vega, Estela
AU  - Servitja, Sònia
AU  - Andrés, Raquel
AU  - Robles, Carlos E
AU  - López, Rafael
AU  - Galve, Elena
AU  - Echarri, María J
AU  - Legeren, Marta
AU  - Moreno, Fernando
PY  - 2020
DO  - 10.1016/j.breast.2020.11.005
UR  - http://hdl.handle.net/10668/16671
T2  - Breast (Edinburgh, Scotland)
AB  - This study evaluated efficacy and safety of palbociclib, a CDK4/6 inhibitor, in heavily-pretreated hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) patients during the...
LA  - en
KW  - Advanced breast cancer
KW  - CDK4/6 inhibitors
KW  - Compassionate use program
KW  - Endocrine therapy
KW  - Palbociclib
KW  - Antineoplastic Agents, Hormonal
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Aromatase Inhibitors
KW  - Breast Neoplasms
KW  - Compassionate Use Trials
KW  - Female
KW  - Fulvestrant
KW  - Humans
KW  - Middle Aged
KW  - Piperazines
KW  - Postmenopause
KW  - Premenopause
KW  - Progression-Free Survival
KW  - Pyridines
KW  - Receptors, Estrogen
KW  - Receptors, Progesterone
KW  - Retrospective Studies
KW  - Spain
KW  - Tamoxifen
KW  - Treatment Outcome
TI  - Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP).
TY  - research article
VL  - 54
ER  -